Entity

Time filter

Source Type

Lincoln, RI, United States

Wen R.,University of Miami | Tao W.,Neurotech | Li Y.,University of Miami | Sieving P.A.,U.S. National Institutes of Health
Progress in Retinal and Eye Research | Year: 2012

Ciliary neurotrophic factor (CNTF) is one of the most studied neurotrophic factors for neuroprotection of the retina. A large body of evidence demonstrates that CNTF promotes rod photoreceptor survival in almost all animal models. Recent studies indicate that CNTF also promotes cone photoreceptor survival and cone outer segment regeneration in the degenerating retina and improves cone function in dogs with congenital achromotopsia. In addition, CNTF is a neuroprotective factor and an axogenesis factor for retinal ganglion cells (RGCs). This review focuses on the effects of exogenous CNTF on photoreceptors and RGCs in the mammalian retina and the potential clinical application of CNTF for retinal degenerative diseases. © 2011 Elsevier Ltd. Source


The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimers disease, Parkinsons disease and Lou Gehrigs disease.


Patent
Neurotech | Date: 2011-03-22

An electrical connector assembly for coupling a first implantable device to a second implantable device, said assembly comprising a male element having one or more male contacts electrically coupled with the first implantable device and a female element comprised of a socket having one or more correspondent female contact electrically coupled with said second implantable device and adapted for receiving said one or more male contact. One or more male contacts are sealed to the male element through a glass or ceramic sealing material. A female contact of said socket comprises a contact structure comprised of a plurality of conductive elongated wires which extend along the internal surface of said the female contact in a hyperboloid arrangement, thereby providing an electrical coupling between the female contact and the corresponding male contact in a plurality of points.


The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrigs disease), spinal muscular atrophy, Alzheimers disease, Parkinsons disease, Huntingtons disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.


Patent
Neurotech | Date: 2015-12-22

The invention relates to a device for delivery of pigment epithelium derived factor (PEDF) to the eye utilizing encapsulated PEDF-secreting cells and related methods for the treatment and prevention of ophthalmic diseases and disorders.

Discover hidden collaborations